Catherine Viscoli, PhD
Senior Research ScientistCards
Appointments
General Internal Medicine
Primary
Neurology
Secondary
Contact Info
About
Titles
Senior Research Scientist
Appointments
General Internal Medicine
Senior Research ScientistPrimaryNeurology
Senior Research ScientistSecondary
Other Departments & Organizations
- General Internal Medicine
- Internal Medicine
- Neurocritical Care
- Neurology
Education & Training
- PhD
- Yale University (1990)
- MPhil
- Yale University, Economics (1983)
- BA
- University of California, San Diego, Economics (1976)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Catherine Viscoli's published research.
Publications Timeline
A big-picture view of Catherine Viscoli's research output by year.
Walter Kernan, MD
Lawrence Young, MD
Janet Henrich, MD
Jeptha Curtis, MD
Steven Pfau, MD
Adam de Havenon, MD, MSCI
58Publications
4,506Citations
Publications
2024
Disability and Recurrent Stroke Among Participants in Stroke Prevention Trials
de Havenon A, Viscoli C, Kleindorfer D, Sucharew H, Delic A, Becker C, Robinson D, Yaghi S, Li V, Lansberg M, Cramer S, Mistry E, Sarpong D, Kasner S, Kernan W, Sheth K. Disability and Recurrent Stroke Among Participants in Stroke Prevention Trials. JAMA Network Open 2024, 7: e2423677. PMID: 39028666, PMCID: PMC11259901, DOI: 10.1001/jamanetworkopen.2024.23677.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsPrevention trialsPoststroke disabilityRecurrent stroke ratesRecurrent strokeCohort studyRate of recurrent strokeStroke Prevention TrialIncreased hazardInsulin Resistance InterventionSecondary prevention trialsBaseline disabilityAssociated with increased ratesStroke rateMain OutcomesFunctional statusResistance InterventionStudy baselineSecondary outcomesPrimary outcomeWorsening heart failureModified Rankin ScaleProfession's participationLong-term followVascular deathDisability
2020
Adherence to study drug in a stroke prevention trial"?>
Kiran A, Viscoli CM, Furie KL, Gorman M, Kernan WN. Adherence to study drug in a stroke prevention trial"?>. Journal Of Stroke And Cerebrovascular Diseases 2020, 29: 105048. PMID: 32912514, PMCID: PMC7487071, DOI: 10.1016/j.jstrokecerebrovasdis.2020.105048.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsRate of discontinuationStudy drugDrug holidayTreatment groupsActive study drugAdverse effectsInsulin Resistance InterventionPremature drug discontinuationRecent ischemic strokeStroke Prevention TrialDouble-blind trialTransient ischemic attackClinical trial researchPhases of adherenceDrug discontinuationIschemic attackStroke preventionDiscontinuation ratesIschemic strokeActive therapyMedical therapyPatient adherencePrevention trialsStroke trialsPharmacodynamic effects
2019
Diabetes prevention and cardiovascular complications
Inzucchi SE, Viscoli CM, Young LH, Kernan WN. Diabetes prevention and cardiovascular complications. Diabetologia 2019, 62: 2161-2162. PMID: 31522231, DOI: 10.1007/s00125-019-04999-3.Peer-Reviewed Original ResearchCitationsPioglitazone Therapy in Patients With Stroke and Prediabetes
Spence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, Ford GA, Gorman M, Furie KL, Lovejoy AM, Young LH, Kernan WN. Pioglitazone Therapy in Patients With Stroke and Prediabetes. JAMA Neurology 2019, 76: 526-535. PMID: 30734043, PMCID: PMC6515584, DOI: 10.1001/jamaneurol.2019.0079.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAcute Coronary SyndromeAgedDiabetes Mellitus, Type 2Disease ProgressionFemaleGlycated HemoglobinHeart FailureHospitalizationHumansHypoglycemic AgentsInsulin ResistanceMaleMedication AdherenceMiddle AgedMyocardial InfarctionPioglitazonePrediabetic StateProportional Hazards ModelsRecurrenceSecondary PreventionStrokeConceptsAcute coronary syndromeStroke/myocardial infarctionTransient ischemic attackMyocardial infarctionCoronary syndromeHeart failureIRIS trialInsulin resistanceGood adherenceIschemic attackRecurrent strokeHazard ratioClinical trialsStroke/transient ischemic attackRandomized multicenter clinical trialAmerican Diabetes Association criteriaInsulin Resistance InterventionHemoglobin A1c levelsEffect of pioglitazoneInsulin-sensitizing agentsMulticenter clinical trialPlasma glucose levelsSerious bone fracturesPlacebo cohortPrior strokeAchievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity
Dearborn JL, Viscoli CM, Young LH, Gorman MJ, Furie KL, Kernan WN. Achievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity. Stroke 2019, 50: 713-717. PMID: 30786849, PMCID: PMC6391736, DOI: 10.1161/strokeaha.118.024008.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTransient ischemic attackBody mass indexProportion of patientsIschemic strokeMass indexVascular eventsBaseline weightWeight lossAchievement of guidelineDays of randomizationRecent ischemic strokeAcute ischemic strokeFuture vascular eventsIschemic attackPlacebo groupObese patientsDiabetes mellitusMedian ageTrial entryIRIS trialMedian timeFunctional outcomeInsulin resistanceClinical trialsPatients
2018
Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk
Viscoli CM, Kent DM, Conwit R, Dearborn JL, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Stuart A, Young LH, Kernan WN, Investigators F. Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk. Stroke 2018, 50: 95-100. PMID: 30580725, PMCID: PMC6557695, DOI: 10.1161/strokeaha.118.022745.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTransient ischemic attackAbsolute risk differenceFracture riskIschemic attackPioglitazone therapyFracture risk modelsIschemic strokeMyocardial infarctionRisk strataRisk differenceRandomized placebo-controlled trialFavorable benefit-risk profilePlacebo-controlled trialLow-risk patientsEffect of pioglitazoneBody mass indexHigh-risk groupBenefit-risk profileHigh-risk stratumLow-risk groupSimple point scoreBone fracture riskCardiovascular riskPatient characteristicsDiabetes mellitusMetabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular disease
Dearborn JL, Viscoli CM, Inzucchi SE, Young LH, Kernan WN. Metabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular disease. International Journal Of Stroke 2018, 14: 639-645. PMID: 30507360, DOI: 10.1177/1747493018816425.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNormal weight patientsMetabolic syndromeMyocardial infarctionWeight patientsCause mortalityInsulin resistanceHigh riskInsulin Resistance InterventionRecent ischemic strokeRecurrent vascular diseaseNon-diabetic patientsTransient ischemic attackAdverse cardiovascular outcomesMajor comorbid conditionsIschemic attackCardiovascular outcomesObesity paradoxIschemic strokeNormal BMIObese patientsStroke populationBetter prognosisComorbid conditionsNormal weightStroke patientsAn Error in An Old Paper Illustrates the Need for Data/Code Archives - Author response
Kernan WN, Viscoli CM, Horwitz RI. An Error in An Old Paper Illustrates the Need for Data/Code Archives - Author response. Journal Of Clinical Epidemiology 2018, 107: 129. PMID: 30465873, DOI: 10.1016/j.jclinepi.2018.11.011.Peer-Reviewed Case Reports and Technical NotesAltmetricMeSH KeywordsHeart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone
Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation 2018, 138: 1210-1220. PMID: 29934374, PMCID: PMC6202153, DOI: 10.1161/circulationaha.118.034763.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRisk of HFTransient ischemic attackEffect of pioglitazoneHF riskHeart failureInsulin-resistant patientsMyocardial infarctionIschemic attackCardiovascular benefitsIschemic strokeDiabetes mellitusInsulin resistanceHigher C-reactive proteinComposite of strokeHF risk scoreHigher HF riskDrug dose reductionHospitalized heart failureIncident myocardial infarctionLower mean doseC-reactive proteinBaseline patient featuresHF hospitalizationCardiovascular eventsPlacebo groupDistance from Home to Research Center: A Barrier to In-Person Visits but Not Treatment Adherence in a Stroke Trial
Leira EC, Viscoli CM, Polgreen LA, Gorman M, Kernan WN. Distance from Home to Research Center: A Barrier to In-Person Visits but Not Treatment Adherence in a Stroke Trial. Neuroepidemiology 2018, 50: 137-143. PMID: 29587267, PMCID: PMC5975097, DOI: 10.1159/000486315.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPerson visitsStroke trialsTreatment adherenceStudy centersInsulin Resistance InterventionLogistic regression modelsIndependent predictorsPreventive careClinical trialsOutcome measuresThird visitPatientsPlace of residenceResistance InterventionSecondary analysisYears of participationVisitsAdherenceGeneralizability of resultsTrialsRural areasTherapyDrugsRegression modelsRecruitment sites
News
News
- November 27, 2022
Internist Dr. Walter Kernan Retires
- April 14, 2022
Discoveries & Impact (April 2022)
- January 11, 2005
Insulin Resistance Intervention after Stroke Focus of $33 Million Grant
- October 25, 2001
Estrogen Therapy Does Not Reduce Risk of Recurrent Stroke or Death, Yale Researchers Find in WEST Study
Get In Touch
Contacts
Academic Office Number